Long-acting HIV prevention injections at your health center
Part of Immune system & allergy, Infections clinical trials.
This study tests a nurse-led program that offers a long-acting injectable medication (cabotegravir) to prevent HIV. The injection is given every two months, and the program aims to make it easier to access this prevention option at your local health center.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to be a patient at one of the participating health centers (for family planning, women's health, STI checks, or other medical care).
- You should be HIV-negative and have a reason to take PrEP (medication to prevent HIV).
- You must be willing to commit to study visits and follow-up, and have a reliable way to be contacted.
- You cannot have had a recent high-risk HIV exposure or symptoms of acute HIV infection in the last month.
- You cannot be currently participating in another clinical trial or planning to move away during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a long-acting injectable HIV prevention medication (called cabotegravir) to see how well it works in real life. If you are already taking or starting this shot, you may be able to join and help improve HIV prevention care.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
This trial tests a long-acting injectable HIV prevention medication (cabotegravir) as an alternative to daily pills. It may be a good fit if you are a man who has sex with men and have been taking oral PrEP consistently.
This study is for people in Louisville who are using or starting long-acting injectable PrEP to prevent HIV. It focuses on understanding your experiences and outcomes with this type of PrEP.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.